ampreloxetine
ampreloxetine: sourced relationships with 1 company · 1 clinical trial tracked.
ampreloxetine evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ampreloxetine → TBPH affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Theravance Biopharma, Inc. (TBPH) Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 |
Clinical Trial Registry Records (1)
A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy
Primary endpoint: Change in OHSA composite score at Week 8 during the double-blind RW period
Frequently asked questions
Which companies have sourced relationships with ampreloxetine?
ampreloxetine has dated SEC/FDA relationship records for Theravance Biopharma, Inc..
How many clinical trials involve ampreloxetine?
BioSniper tracks 1 clinical trial involving ampreloxetine.